BIO-key to be Delisted from Nasdaq, Shares Move to OTC Markets
Summary
BIO-key International announced its common stock will be suspended from Nasdaq and moved to OTC Markets due to non-compliance with bid price and annual report filing rules.
Key Events
-
Nasdaq Delisting Imminent
Trading of BIO-key's common stock will be suspended from the Nasdaq Capital Market at the opening of business on May 13, 2026, with a Form 25-NSE to be filed for removal from listing and registration.
-
Dual Compliance Failures
The delisting is due to the company's failure to regain compliance with Nasdaq's $1.00 minimum bid price rule and its failure to file the Annual Report on Form 10-K for the year ended December 31, 2025.
-
Transition to OTC Markets
Effective with the opening of trading on May 13, 2026, the company's common stock will be traded on OTC Markets under the ticker symbol 'BKYI'.
-
Appeal Intended
BIO-key intends to timely request a hearing before a Nasdaq Hearings Panel to appeal the delisting determination and seek to regain compliance.
Analysis
BIO-key International's common stock will be suspended from Nasdaq and moved to the less liquid OTC Markets due to two critical compliance failures: not maintaining the $1.00 minimum bid price for the required period and failing to file its Annual Report on Form 10-K for 2025. This delisting, occurring while the stock trades near its 52-week low, significantly impacts the company's visibility and access to institutional capital, despite management's intent to appeal and positive business outlook.
At the time of this filing, BKYI was trading at $3.23 on NASDAQ in the Technology sector, with a market capitalization of approximately $3.8M. The 52-week trading range was $3.40 to $19.70. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.